Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mikel Berdud
Observed names:
Berdud García-López, Mikel,
Berdud, Mikel,
M Berdud,
M. Berdud,
M. Berdud.
Institution:
Office Of Health Economics
Observed institutions:
Universidad Pública de Navarra (UPNA),
Office Of Health Economics,
Swedish Institute for Health Economics,
Universidad de Navarra
ORCID:
0000-0002-4816-5272
Observed ORCID:
0000-0002-4816-5272
OpenAlex ID:
A5055338533
Biosimilars: How Can Payers Get Long-Term Savings?
2016
·
Jorge Mestre-Ferrandiz
, Adrian Towse
, et al.
·
PharmacoEconomics
·
87
PDF
Establishing a reasonable price for an orphan drug
2020
·
Mikel Berdud
, Michael Drummond
, et al.
·
Cost Effectiveness and Resource Allocation
·
84
PDF
Incentives and intrinsic motivation in healthcare
2016
·
Mikel Berdud
, Juan M. Cabasés
, et al.
·
Gaceta Sanitaria
·
67
PDF
A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach
2023
·
Mikel Berdud
, Jimena Ferraro
, et al.
·
Frontiers in Health Services
·
15
PDF
The Future of Global Health Procurement: Issues around Pricing Transparency
2019
·
Mikel Berdud
, Kalipso Chalkidou
, et al.
·
RePEc: Research Papers in Economics
·
7
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom
2023
·
Mikel Berdud
, Niklas Wallin-Bernhardsson
, et al.
·
Value in Health
·
6
PDF
Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
2016
·
Mikel Berdud
, Adrian Towse
, et al.
·
Oxford Review of Economic Policy
·
6
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
2018
·
Mikel Berdud
, Martina Garau
, et al.
·
RePEc: Research Papers in Economics
·
4
What do pharmaceuticals really cost in the long run?
2017
·
Darius Lakdawalla
, Joanna P MacEwan
, et al.
·
PubMed
·
4
Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?
2025
·
Matthias P Hofer
, Priscila Radu
, et al.
·
Health Affairs Scholar
·
3
PDF
Pns99 a Theory on Icer Pricing and Optimal Level of Cost-effectiveness Threshold
2020
·
M. Berdud
, J. Ferraro
, et al.
·
Value in Health
·
3
Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases
2022
·
Dimitrios Kourouklis
, Mikel Berdud
, et al.
·
Applied Economics Letters
·
1
A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
2020
·
M. Berdud.
, J. Ferraro.
, et al.
·
1
PP170 Quantifying the Life-Cycle Value of Second Generation Antipsychotics
2019
·
Mikel Berdud
, Niklas Wallin-Bernhardsson
, et al.
·
International Journal of Technology Assessment in Health Care
·
1
PDF
Biosimilars: achieving long-term savings and competitive markets
2016
·
Jorge Mestre-Ferrandiz
, Adrian Towse
, et al.
·
Generics and Biosimilars Initiative Journal
·
1
PDF
Hpr148 Us Medicine Pricing Policy Changes: Impact on the Full Biopharmaceutical Investment Ecosystem
2026
·
Matthias Hofer
, Priscila Radu
, et al.
·
Value in Health
WP1 - Deliverable 1.1: Stakeholders judgement on barriers and enablers of novel payment/pricing schemes
2026
·
Darrow, Brittany
, Hodgson, Sian
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
WP1 - Milestone 2: Within-country performance of novel payment/pricing schemes: costs and benefits of implementation
2026
·
Hofer, Matthias
, Berdud, Mikel
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
WP1 - Deliverable 1.2: Policy recommendations about successful and flexible implementation of the different schemes to promote access to high-quality affordable innovative health technologies
2026
·
ARDITO, VITTORIA
, Berdud, Mikel
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
HPR75 Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe
2025
·
Mikel Berdud
, Matthias Hofer
, et al.
·
Value in Health
HPR230 Unlocking Access: Overcoming Barriers and Harnessing Enablers for Innovative Payment Models for Pharmaceutical Innovation in Europe
2025
·
Sian Hodgson
, Brittany Darrow
, et al.
·
Value in Health
P51 How Can We Make Innovative Payment and Pricing Schemes Work? Findings of the European Union Research Project HI-PRIX
2025
·
Michael Drummond
, Vittoria Ardito
, et al.
·
Value in Health
HTA183 Setting the Right Discount Rate for Health Technology Assessment in the Slovak Republic
2023
·
P. Cubi-Molla
, J. Hitch
, et al.
·
Value in Health
PDF
EE664 The Basis for a New Framework to Determine the Cost-Effectiveness Threshold
2022
·
M Berdud
, C Sampson
, et al.
·
Value in Health
PDF
POSA213 Product Development Partnerships (PDPS) and Pharmaceutical Innovation
2022
·
M Berdud
, M Jofre-Bonet
, et al.
·
Value in Health
Show more works
View as search
Works count:
45
Citation count:
290
H-index:
6
I10-index:
4
Year
Topic
Type